Biopharma industry’s vaccine pipeline lacks ‘depth,’ with an overemphasis on Covid — report

There are too many Covid vac­cines in de­vel­op­ment, and many oth­er in­fec­tious dis­eases where lit­tle work is get­ting done by biotech and phar­ma com­pa­nies.

That’s the con­clu­sion of a new re­port from the Biotech­nol­o­gy In­no­va­tion Or­ga­ni­za­tion, or BIO, which found that of the 249 nov­el vac­cine pro­grams be­ing test­ed in hu­mans around the world, 28% were for the pre­ven­tion of Covid-19. On­ly 20% of dis­eases have five or more on­go­ing clin­i­cal pro­grams. And some preva­lent threats, like West Nile virus and Ly­me dis­ease, have just one vac­cine in clin­i­cal de­vel­op­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.